195 related articles for article (PubMed ID: 22829202)
1. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.
Kirane A; Toombs JE; Ostapoff K; Carbon JG; Zaknoen S; Braunfeld J; Schwarz RE; Burrows FJ; Brekken RA
Clin Cancer Res; 2012 Sep; 18(18):5031-42. PubMed ID: 22829202
[TBL] [Abstract][Full Text] [Related]
2. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
J Cell Biochem; 2010 May; 110(1):171-81. PubMed ID: 20213764
[TBL] [Abstract][Full Text] [Related]
3. Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib.
Kirane A; Toombs JE; Larsen JE; Ostapoff KT; Meshaw KR; Zaknoen S; Brekken RA; Burrows FJ
Carcinogenesis; 2012 Sep; 33(9):1639-46. PubMed ID: 22678114
[TBL] [Abstract][Full Text] [Related]
4. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
5. Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies.
St John MA; Wang G; Luo J; Dohadwala M; Hu D; Lin Y; Dennis M; Lee JM; Elashoff D; Lawhon T; Zaknoen SL; Burrows FJ; Dubinett SM
Br J Cancer; 2012 Aug; 107(4):707-12. PubMed ID: 22828609
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Lu YY; Jing DD; Xu M; Wu K; Wang XP
World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.
Ali S; El-Rayes BF; Sarkar FH; Philip PA
Mol Cancer Ther; 2005 Dec; 4(12):1943-51. PubMed ID: 16373709
[TBL] [Abstract][Full Text] [Related]
8. Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer.
Rao PN; Grover RK
IDrugs; 2009 Nov; 12(11):711-22. PubMed ID: 19844858
[TBL] [Abstract][Full Text] [Related]
9. Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
Wang X; Zhang L; O'Neill A; Bahamon B; Alsop DC; Mier JW; Goldberg SN; Signoretti S; Atkins MB; Wood CG; Bhatt RS
Br J Cancer; 2013 Feb; 108(2):319-26. PubMed ID: 23322198
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.
Ali S; Banerjee S; Ahmad A; El-Rayes BF; Philip PA; Sarkar FH
Mol Cancer Ther; 2008 Jun; 7(6):1708-19. PubMed ID: 18566242
[TBL] [Abstract][Full Text] [Related]
11. A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.
Ding N; Cui XX; Gao Z; Huang H; Wei X; Du Z; Lin Y; Shih WJ; Rabson AB; Conney AH; Hu C; Zheng X
Int J Oncol; 2014 Jun; 44(6):2139-45. PubMed ID: 24647860
[TBL] [Abstract][Full Text] [Related]
12. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.
Rahman M; Selvarajan K; Hasan MR; Chan AP; Jin C; Kim J; Chan SK; Le ND; Kim YB; Tai IT
Neoplasia; 2012 Jul; 14(7):624-33. PubMed ID: 22904679
[TBL] [Abstract][Full Text] [Related]
15. Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Ninomiya I; Nagai N; Oyama K; Hayashi H; Tajima H; Kitagawa H; Fushida S; Fujimura T; Ohta T
Oncol Rep; 2012 Sep; 28(3):777-84. PubMed ID: 22751903
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
Rao CV; Janakiram NB; Madka V; Devarkonda V; Brewer M; Biddick L; Lightfoot S; Steele VE; Mohammed A
Oncotarget; 2015 Oct; 6(32):33290-305. PubMed ID: 26429877
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Lin J; Wu H; Shi H; Pan W; Yu H; Zhu J
PLoS One; 2013; 8(10):e76169. PubMed ID: 24155892
[TBL] [Abstract][Full Text] [Related]
19. Triptolide induces apoptosis and inhibits the growth and angiogenesis of human pancreatic cancer cells by downregulating COX-2 and VEGF.
Ma JX; Sun YL; Wang YQ; Wu HY; Jin J; Yu XF
Oncol Res; 2013; 20(8):359-68. PubMed ID: 23924856
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of GEP100 Improved the Growth Inhibition Effect of Erlotinib Through Modulating Mesenchymal Epithelial Transition Process in Pancreatic Cancer.
Xie CG; Sun SL; Wei SM; Xu XM; Shao LM; Chen JM; Cai JT
Pancreas; 2018 Jul; 47(6):732-737. PubMed ID: 29851753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
